Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).

Authors

null

Rodabe Navroze Amaria

The University of Texas MD Anderson Cancer Center, Houston, TX

Rodabe Navroze Amaria , Sangeetha Meda Reddy , Hussein Abdul-Hassan Tawbi , Michael A. Davies , Merrick I. Ross , Isabella Claudia Glitza , Janice N. Cormier , Carol M. Lewis , Wen-Jen Hwu , Ehab Y. Hanna , Adi Diab , Michael K.K. Wong , Richard Eldon Royal , Neil D. Gross , Randal S. Weber , Stephen Yenzen Lai , Richard A. Ehlers Jr., Elizabeth M. Burton , Michael T. Tetzlaff , Jennifer Ann Wargo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02519322

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9510)

DOI

10.1200/JCO.2018.36.15_suppl.9510

Abstract #

9510

Poster Bd #

337

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.

Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.

First Author: Michael C. Lowe

First Author: Lisanne P. Zijlker

First Author: Faisal Fa'ak

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.

Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.

First Author: Kruti Bhagirath Vora